Dr. Frances Guyett, CEO
Appointed in 2006 as CEO, Dr. Guyett brings tremendous experience of the pharmaceutical and biotechnology industries to RDDT Laboratories. Previously, Dr. Guyett actively managed numerous quality accredited contract research organizations within the preclinical toxicology, human toxicology, genetic, microbiology, human and molecular pathology areas.
Dr. Guyett has in excess of 20 years experience in senior executive roles in the pharmaceutical and biotechnology industries both here in Australia and overseas especially in the USA and Japan. Her experience in the multi-national pharmaceutical companies include Bristol-Myers Squibb, Searle (USA and Japan) and Pharmacia (USA and Japan) in various roles such as Director for Asia Pacific / Latin America, Business Development Director, Group Business Manager, Marketing Manager etc. During Dr. Guyett's time overseas, she worked in Japan and USA preparing for the launch of a new cardiovascular drug called Inspra (eplerenone) from Phase II to regulatory approval for the USA, Asia Pacific and Latin America regions.
Dr. Guyett received her Ph.D. and M.B.A. from Monash University, B.Sc. (Hons) from Melbourne University, and GAICD. Also, she has experience as a member on various Boards and Audit Committees.
Dr. Peter Tapley, Research Director
Dr. Tapley joined RDDT Laboratories as Research Director in May 2006. In this role he is responsible for all scientific operations and also has a key role as a study director on GLP rodent toxicology studies. Dr. Tapley has a wide understanding of drug discovery and development processes based on 15 plus years of experience in the biotechnology and pharmaceutical industry. His resume includes post-doctoral training at the Fred Hutchinson Cancer Research Centre in Seattle, and Bristol Myers Squibb in Princeton. He also has US industry experience, initially at Ligand Pharmaceuticals in San Diego. Subsequently at GlaxoSmithKline in Philadelphia he was program co-leader of a novel small molecule for treatment of thrombocytopenia at GlaxoSmithKline which progressed through pre-clinical studies to clinical studies. Dr. Tapley has also actively contributed to the Australian biotechnology sector at GroPep Ltd and at Cortical Pty Ltd. Dr. Tapley is a member of the American Association for Cancer Research and the American Society of Hematology.
Dr. LiQing Tu, Quality Manager
Dr. Tu has MBBS and Master degree in Medicine, in conjunction with a PhD degree in toxicology. Prior to joining RDDT Laboratories, Dr Tu worked at Fujian Medical University of China as a Lecturer and Research Fellow. Her research interests included new drug/chemical safety evaluation and cardiovascular toxicity research utilising both animal models and human epidemiology methods.
Dr. Tu has extensive experience in preclinical GLP and ISO drug safety testing. She has managed the establishment of the RDDT Laboratories GLP and ISO 17025 Quality System which was accredited in 2004. She has subsequently successfully maintained RDDT GLP and ISO accreditation and managed the expansion of the GLP service scope. Dr. Tu also plays a key role in quality assurance of commercial projects and internal and external audits.
Dr. Tu is a member of both the British Association of Research Quality Assurance (BARQA) and US Society of Quality Assurance (SQA, US).